Tuesday, 24 March 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 24 March 2026
News

Manufacturing site inks deal

Posted 23 March 2026 PM

Australia’s first commercial viral-vector manufacturing site, the Viral Vector Manufacturing Facility (VVMF) has inked a five-year deal to use OXB’s platforms.

OXB is one of the original pioneers in gene and cell therapy and has collaborated with big pharmas, including AstraZeneca, BMS, Boehringer Ingelheim, and Novartis.

To see the whole article, please login

Popular

Ex-J&J staffer sued for secrets 'theft'
Who's back in Aust for a new role?
Novo slapped with Warning Letter
Manufacturing site inks deal
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home